This Editorial highlights a paper in the journal issue (pp. 128-138) entitled 'A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis,' which details several novel findings, each of which may have important effects in the development of new drugs for the treatment of tuberculosis.
Burman, W.; McNeeley, D.; Moulton, L.H.; Spigelman, M.; Vernon, A. Editorial: Advancing the science in clinical trials for new TB drugs. International Journal of Tuberculosis and Lung Disease (2008) 12 (2) 111-112.